Cover Image

Cordycepin Targets HRD1 to Promote Cancer Cell PD‐L1 Ubiquitin–Proteasome Degradation and Increase Antitumor Immunity

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Xiangxin Geng, Minchen Cai, Hongmei Hu, Mengting Xu, Qing Zhang, Hanchen Xu, Dianping Yu, Hongwei Zhang, Hanchi Xu, Linyang Li, Mengmeng Guo, Shize Xie, Qun Wang, Weidong Zhang, Sanhong Liu
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	MedComm
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

5,7,4′‐Trimethoxyflavone triggers cancer cell PD‐L1 ubiquitin–proteasome degradation and facilitates antitumor immunity by targeting HRD1
by: Jianhua Xia, et al.
Published: (2024)

Targeting the Ubiquitin–Proteasome System for Cancer
by: Zhaoyun Liu, et al.
Published: (2025)

Midnolin Ubiquitination is Required for its Proteasome‐Mediated Degradation
by: Jiang He, et al.
Published: (2025)

Natural Killer Cell‐Mediated Antitumor Immunity: Molecular Mechanisms and Clinical Applications
by: Nanzhi Luo, et al.
Published: (2025)

Intercellular Mitochondrial Transfer Enhances the Antitumor Immunity of CD8+ T Cells
by: Ce Guo, et al.
Published: (2025)

Activation of Adenosine Phosphate Signaling Promotes Antitumor Immunity in Tumor Microenvironment and Facilitate Immunotherapy
by: Yantao Xu, et al.
Published: (2025)

Non‐stoichiometric Sodium Chloride Reprograms Ionic Homeostasis to Enhance Antitumor Immunity
by: Chongxiao Wang, et al.
Published: (2025)

Synergistic PD‐1/LAG‐3 Inhibition: Mechanistic Insights and Implications for Enhanced Tumor Immunotherapy
by: Jianqiao Shentu, et al.
Published: (2025)

Toll‐Like Receptors in the Immunotherapy Era: Dual‐Edged Swords of Tumor Immunity and Clinical Translation
by: Nueraili Maihemuti, et al.
Published: (2025)

Clinical Benefit of PD‐1/PD‐L1 Inhibitors as Standard First‐Line Treatment in Low PD‐L1‐Expressing Advanced Solid Tumors: A Systematic Review and Meta‐Analysis
by: Peng Wu, et al.
Published: (2026)

Platelet‐to‐Neutrophil Ratio: A Novel Prognostic Indicator for Anti‐PD‐1‐Based Therapy in Relapsed/Refractory Hodgkin Lymphoma and Solid Tumors
by: Yuting Pan, et al.
Published: (2025)

Integrated Multi‐Omics Profiling to Characterize Molecular Subtypes and Reveal Potential Therapeutic Strategies for Colorectal Cancer
by: Xin Guo, et al.
Published: (2025)

Sulforaphane Synergizes With PD‐1 Blockade Through Activating CD8 + T Cells in Non–Small Cell Lung Cancer: Preclinical and Clinical Investigations
by: Jieyao Li, et al.
Published: (2026)

Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies
by: Peng Gao, et al.
Published: (2025)

Targeted Deletion of Peroxiredoxin 1 Enhances Anti‐Tumor Immunity in Colorectal Cancer by Reprogramming the Immunosuppressive Tumor‐Associated Macrophages
by: Yuqi Sun, et al.
Published: (2025)

Trained Immunity in Health and Disease
by: Meng Yao, et al.
Published: (2025)

Maresin‐1 ameliorates hypertensive vascular remodeling through its receptor LGR6
by: Zheng Yin, et al.
Published: (2024)

The Incremental Prognostic Value of Hyperemic Coronary Flow Velocity in Patients with Angina and Nonobstructive Coronary Artery Disease
by: Quande Liu, et al.
Published: (2026)

Changes in L‐phenylalanine concentration reflect and predict response to anti‐PD‐1 treatment combined with chemotherapy in patients with non‐small cell lung cancer
by: Yaqing Liu, et al.
Published: (2025)

A novel allosteric driver mutation of β‐glucuronidase promotes head and neck squamous cell carcinoma progression through STT3B‐mediated PD‐L1 N‐glycosylation
by: Zhonglong Liu, et al.
Published: (2025)

KSQ‐4279, an Inhibitor of Ubiquitin Specific Peptidase 1, Enhanced the Chemotherapeutic Efficacy in ABCB1/ABCG2/ABCC1‐Mediated Multidrug Resistant Cancers
by: Qihong Yang, et al.
Published: (2025)

Intranasal Mosaic H1N1 Live Attenuated Influenza Vaccine Elicits Broad Cross‐Reactive Immunity and Protection Against Group 1 and 2 Influenza A Viruses
by: Ximeng Ma, et al.
Published: (2025)

Peripheral Blood Mononuclear Cells Profiling Revealed Biomarkers That Predict PD‐1 Inhibitor‐Induced Immune‐Related Adverse Events
by: Jun Wang, et al.
Published: (2026)

E3 Ubiquitin Ligases: Structures, Biological Functions, Diseases, and Therapy
by: Haochen Wang, et al.
Published: (2025)

PD‐1/PD‐L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First‐Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study
by: Riqing Huang, et al.
Published: (2025)

NFKB2 mediates colorectal cancer cell immune escape and metastasis in a STAT2/PD‐L1‐dependent manner
by: Jiwei Zhang, et al.
Published: (2024)

Acute Myocardial Infarction: Molecular Pathogenesis, Diagnosis, and Clinical Management
by: Mengmeng Zhu, et al.
Published: (2025)

Impaired Cellular Immunity and Cross‐Reactive Humoral Responses to Mpox Virus in HIV‐Infected Individuals Vaccinated with Vaccinia Virus Tiantan Strain
by: Qiao Zhang, et al.
Published: (2025)

Ubiquitin‐specific protease 22 controls melanoma metastasis and vulnerability to ferroptosis through targeting SIRT1/PTEN/PI3K signaling
by: Huiyan Sun, et al.
Published: (2024)

Oncolytic Therapy: Delivery System and New Therapeutic Strategies for Cancer
by: Sikan Jin, et al.
Published: (2026)

Addition of anti‐PD‐1 immunotherapy to BRAF inhibitor‐based targeted therapy improves real‐world survival and delays brain metastases in patients with BRAFV600‐mutant advanced melanoma: a multicenter cohort study
by: Junwan Wu, et al.
Published: (2025)

Dual MNK/VEGFR2 Inhibitor JDB153 Enhances Immunotherapeutic Efficiency and Chemosensitivity in Lung Cancer
by: Maosen Xu, et al.
Published: (2025)

Chromosome 1 Open Reading Frame 35 Drives Colorectal Cancer Progression by Enhancing Tumor‐Intrinsic Proliferation and CD8 + T Cell Suppression
by: Shaosen Zhang, et al.
Published: (2026)

Liquid–liquid phase separation in diseases
by: Xinyue Zhang, et al.
Published: (2024)

Metabolic Reprogramming of the Pre‐Metastatic Niche: A Sweet Spot for Anti‐Tumor Immunity
by: Xuan Zhang, et al.
Published: (2026)

Targeting CD300ld to normalize the tumor microenvironment: an emerging insight in cancer immunotherapy
by: Lin‐Zhu Zhang, et al.
Published: (2024)

HCoV‐HKU1 and TMPRSS2 interaction: uncovering mechanisms of viral invasion
by: Zehan Pang, et al.
Published: (2025)

PDPN+ cancer‐associated fibroblasts enhance gastric cancer angiogenesis via AKT/NF‐κB activation and the CCL2‐ACKR1 axis
by: Zhenxiong Zhao, et al.
Published: (2025)

Short‐Term, Cycle‐Synchronized Adjunctive Therapy With Crocus Total Glucosides Tablets for Cardiac Protection Against Cancer Therapy‐Related Cardiac Dysfunction in Breast Cancer Patients: A Randomized, Double‐Blind, Placebo‐Controlled Trial
by: Xiaoling Liu, et al.
Published: (2026)

Depletion of Fat Mass and Obesity‐Associated Protein (FTO) Drives Heterochromatin Loss via Lysine Acetyltransferase 8 (KAT8)‐Mediated Remodeling and Spacing Factor 1 (RSF1) Acetylation in Skin Aging
by: Fan Wang, et al.
Published: (2025)